Residency · Residency · Urology

Evaluation of the Renal Mass: Imaging and Biopsy

Overview

The evaluation of renal masses relies heavily on imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasound (CEUS). These techniques provide critical information about lesion characteristics that guide diagnosis and management. The Bosniak classification system, updated in 2019, remains a cornerstone for categorizing cystic renal masses based on imaging features. Renal mass biopsy plays an important role in selected cases to obtain histologic diagnosis, particularly when considering active surveillance for small renal masses.

Epidemiology of Renal Masses

The incidental detection of renal masses has increased substantially due to the widespread use of cross-sectional imaging techniques. Approximately 60-70% of renal masses are discovered incidentally during imaging performed for unrelated reasons. Among small renal masses (SRMs), defined as lesions measuring 4 cm or less, about 20-30% are benign entities such as oncocytoma or angiomyolipoma (AML). Renal cell carcinoma (RCC) accounts for roughly 3% of all adult malignancies, with a peak incidence between 60 and 70 years of age and a male-to-female ratio of approximately 2:1. Established risk factors for RCC include smoking, obesity, hypertension, von Hippel-Lindau (VHL) disease, and acquired cystic kidney disease, particularly in patients on dialysis.

Imaging Modalities

CT (Preferred Initial Modality)

CT is the preferred initial imaging modality for evaluating renal masses due to its widespread availability and excellent spatial resolution. The examination typically includes multiple phases. The non-contrast phase establishes baseline lesion density measured in Hounsfield units (HU) and identifies calcifications or macroscopic fat. The corticomedullary (arterial) phase delineates renal arterial anatomy and characterizes hypervascular tumors. The nephrographic phase is the most sensitive for detecting renal masses and is optimal for characterizing solid lesions. The excretory (delayed) phase evaluates the collecting system and ureters, useful in CT urography. Enhancement is defined as an increase of more than 20 HU from the non-contrast to the enhanced phase, which suggests a solid lesion is enhancing and thus suspicious for malignancy. However, pseudoenhancement, an artifactual increase of 10-15 HU seen in small intrarenal cysts, should not be overinterpreted as true enhancement.

MRI

MRI offers superior soft tissue contrast without ionizing radiation and is particularly useful when CT contrast is contraindicated or when CT findings are indeterminate. Key MRI sequences include T1-weighted images before and after gadolinium contrast to assess enhancement patterns, T2-weighted images to evaluate fluid content and cystic characteristics, and in-phase/opposed-phase imaging to detect intracellular fat. Clear cell RCC typically shows signal dropout on opposed-phase images due to intracellular lipid, whereas AML contains macroscopic fat. Diffusion-weighted imaging (DWI) can identify restricted diffusion, which correlates with higher cellularity and malignancy. MRI is also superior for detecting tumor thrombus extending into the renal vein or inferior vena cava.

Contrast-Enhanced Ultrasound (CEUS)

CEUS uses microbubble contrast agents such as sulfur hexafluoride to assess real-time enhancement patterns without nephrotoxicity or radiation exposure. It is useful for characterizing indeterminate cystic lesions, monitoring known small renal masses, and in patients with contrast allergies. The Bosniak classification can be applied to CEUS findings, although its use is limited by patient body habitus and operator dependence.

Conventional Ultrasound

Conventional ultrasound is often the initial modality detecting incidental renal masses. It can reliably distinguish simple cysts from solid lesions but cannot adequately characterize complex cystic or solid masses, necessitating further evaluation with CT or MRI.

Bosniak Classification of Renal Cysts (2019 Update)

The Bosniak classification system stratifies cystic renal lesions based on imaging features to estimate malignancy risk and guide management. Class I cysts are simple, with thin walls, no septa, calcifications, or enhancement, and carry virtually no risk of malignancy; no follow-up is required. Class II lesions have a few thin septa less than 3 mm, fine calcifications, or are hyperdense cysts measuring 3 cm or less that are homogeneous and non-enhancing; these also have negligible malignancy risk and do not require follow-up. Class IIF lesions display multiple thin septa or minimally thickened septa measuring 3 mm, thick or nodular calcifications, or non-enhancing hyperdense cysts larger than 3 cm; these carry a 5-10% risk of malignancy and warrant follow-up imaging initially at 6 months and then annually for five years. Class III cysts have thickened enhancing septa or wall thickening of 4 mm or more, with approximately 50% risk of malignancy; management options include surgery or active surveillance. Class IV lesions contain enhancing soft tissue components and have a malignancy risk of about 90%, necessitating surgical treatment as renal cell carcinoma.

The 2019 update introduced measurable thresholds for wall and septal thickness (3 mm and 4 mm) to reduce subjectivity and interobserver variability. The classification now applies to both CT and MRI, whereas previously it was limited to CT. Hyperdense cysts that are homogeneous, non-enhancing, and 3 cm or smaller are reclassified as class II, whereas they could have been class IIF before. MRI-specific features, such as T1-bright cysts, were also incorporated.

Solid Renal Mass Characterization

Clear cell RCC, which accounts for 70-80% of RCCs, typically appears hypervascular with avid enhancement during the corticomedullary phase followed by washout. These tumors are often heterogeneous, containing areas of necrosis, hemorrhage, or cystic change. On MRI, clear cell RCC shows signal dropout on opposed-phase imaging due to intracellular lipid. This subtype has variable prognosis depending on tumor grade.

Papillary RCC represents 10-15% of cases and is hypovascular, showing minimal enhancement and homogeneous low attenuation on CT. On MRI, papillary RCC exhibits low T2 signal intensity, restricted diffusion, and may contain hemosiderin deposits. Type 1 papillary RCC, which is basophilic, generally has a better prognosis than the eosinophilic Type 2 variant.

Chromophobe RCC comprises about 5% of cases and demonstrates moderate, homogeneous enhancement. These tumors are typically large, well-circumscribed, and may have a central scar. Chromophobe RCC generally has a favorable prognosis.

Oncocytomas are benign renal masses accounting for 3-7% of cases. They may show a central stellate scar, although this feature is present in only about 30% and is not pathognomonic. Oncocytomas enhance homogeneously and may display a spoke-wheel vascular pattern on angiography. Imaging cannot reliably distinguish oncocytoma from chromophobe RCC, so biopsy or surgical excision is often required for definitive diagnosis.

Angiomyolipomas (AMLs) are benign tumors characterized by the presence of fat. Fat-containing AMLs demonstrate macroscopic fat with negative HU values on non-contrast CT, which is pathognomonic and obviates the need for biopsy or surgery unless symptomatic or large. Management involves observation if the lesion is less than 4 cm and asymptomatic, while embolization or surgery is considered for lesions larger than 4 cm, symptomatic cases, or women of childbearing age due to bleeding risk. Fat-poor AMLs lack macroscopic fat on CT and can mimic RCC. MRI with chemical shift imaging may detect microscopic fat, but biopsy is often necessary to differentiate these lesions from malignancy.

Renal Mass Biopsy

Biopsy of renal masses is indicated in several clinical scenarios. It is recommended for small renal masses (≤4 cm) when active surveillance is being considered, prior to ablative therapies such as cryoablation or radiofrequency ablation, and when metastatic disease to the kidney is suspected, including lymphoma or metastases from lung or breast cancer. Biopsy is also useful when infection or abscess is suspected, in cases of bilateral or multifocal masses, and when oncocytoma or AML is suspected to avoid unnecessary surgery. Additionally, biopsy may be warranted in patients with significant comorbidities where histologic diagnosis would influence management decisions.

The procedure is typically performed under CT or ultrasound guidance using an 18-gauge coaxial core needle. Two to three cores are obtained from the peripheral viable tissue, avoiding central necrosis. Fine needle aspiration alone is inadequate because architectural and immunohistochemical information is necessary for accurate diagnosis. Complications are uncommon, occurring in less than 5% of cases, with hematoma being the most frequent; serious hemorrhage is rare. Tumor seeding along the needle tract is exceedingly rare, with an incidence below 0.01%.

Modern biopsy techniques yield a sensitivity for malignancy of 90-95% and specificity greater than 95%. However, non-diagnostic results occur in 10-20% of cases and may necessitate repeat biopsy. Concordance with surgical pathology is high for tumor type (85-90%) but lower for tumor grade (70-80%). When oncocytic neoplasm is identified on biopsy, it is often not possible to distinguish oncocytoma from chromophobe RCC definitively.

Biopsy is not indicated when classic imaging features of AML with macroscopic fat are present, as the diagnosis is radiologic. It is also generally avoided in young, healthy patients with classic enhancing solid masses who will undergo surgery regardless. Cystic masses are poor biopsy candidates due to the risk of cyst rupture and low diagnostic yield. When there is high clinical suspicion for RCC and the patient is a surgical candidate, biopsy is unlikely to alter management and is therefore not routinely performed.

Active Surveillance for Small Renal Masses

Active surveillance is a management strategy for small renal masses, particularly those measuring 4 cm or less. This approach is justified because 20-30% of SRMs are benign, and even malignant SRMs often exhibit indolent behavior characterized by low grade and slow growth. The average growth rate during surveillance is approximately 0.3 cm per year, and metastatic progression occurs in only 1-2% of cases. Active surveillance is especially suitable for elderly patients, those with significant comorbidities, or individuals with competing mortality risks.

The surveillance protocol typically includes an initial biopsy, if feasible, to confirm histology. Cross-sectional imaging is performed every 3 to 6 months during the first year and then every 6 to 12 months thereafter. Intervention is considered if the tumor grows more than 0.5 cm per year, reaches the 4 cm size threshold, demonstrates changes in imaging characteristics such as necrosis or invasion, or if the patient prefers treatment. Delayed intervention in appropriately selected patients does not compromise oncologic outcomes.

Thermal ablation serves as an alternative to surgery for small renal masses. Cryoablation involves percutaneous or laparoscopic freezing of the tumor to temperatures between -20 and -40°C, typically using a double freeze-thaw cycle. Radiofrequency ablation (RFA) uses heat-based destruction at 60-100°C, while microwave ablation is an emerging modality. These techniques are best suited for tumors 3 cm or smaller that are exophytic and not adjacent to the collecting system or renal hilum. Although thermal ablation has a higher local recurrence rate (5-10%) compared to partial nephrectomy (1-3%), it is appropriate for patients who are not surgical candidates or who refuse surgery. Biopsy at the time of ablation is mandatory to confirm diagnosis.

<image>A side-by-side comparison of CT images showing the Bosniak classification of renal cysts from class I through IV. Each panel shows a representative axial CT image (contrast-enhanced) with labeled features: Class I (simple cyst, thin wall, no enhancement), Class II (thin septa, fine calcification), Class IIF (multiple thin septa, minimally thickened), Class III (thickened enhancing septa/wall), and Class IV (enhancing soft tissue nodule). Malignancy risk percentages are annotated for each class. Radiologic education format with CT window/level settings indicated.</image>

<image>A diagnostic algorithm flowchart for evaluation of an incidentally discovered renal mass. Starting with initial imaging finding, branches to cystic (apply Bosniak classification) vs. solid mass. Solid mass branches to: macroscopic fat present (AML, manage by size) vs. enhancing solid mass. Enhancing mass branches based on size: ≤4 cm (SRM — consider biopsy, active surveillance, ablation, or partial nephrectomy) vs. >4 cm (partial or radical nephrectomy based on complexity). Decision nodes include biopsy indications, patient fitness assessment, and imaging characteristics. Clean clinical algorithm format.</image>

<image>A comparison panel of typical imaging appearances of common renal mass subtypes on contrast-enhanced CT: clear cell RCC (hypervascular, heterogeneous enhancement), papillary RCC (hypovascular, homogeneous, low enhancement), chromophobe RCC (moderate homogeneous enhancement), oncocytoma (central scar, homogeneous enhancement), and angiomyolipoma (macroscopic fat with negative HU). Each panel includes key imaging features and distinguishing characteristics. Radiology teaching file format.</image>

Clinical Pearls

Enhancement of more than 20 HU on CT is the critical imaging finding that distinguishes a potentially malignant solid renal mass from a benign cyst, so it is essential to always compare pre- and post-contrast images carefully. The 2019 Bosniak update introduced measurable criteria for wall and septal thickness at 3 mm and 4 mm thresholds, which reduce subjectivity and improve reproducibility; learning these specific cutoffs is important. The presence of macroscopic fat, identified as negative HU values on non-contrast CT, is pathognomonic for angiomyolipoma, and in such cases, biopsy and surgery are not required. Renal mass biopsy has a non-diagnostic rate of 10-20%, so patients should be counseled that repeat biopsy may be necessary and that a non-diagnostic result does not exclude malignancy. Active surveillance is a safe approach for well-selected patients with small renal masses, particularly elderly individuals with competing comorbidities, given the low average growth rate of 0.3 cm per year and the rarity of metastatic progression. Oncocytoma cannot be reliably distinguished from chromophobe RCC by imaging or biopsy alone; if this distinction is critical for management, surgical excision may be necessary. Fat-poor AML can mimic RCC on CT and often requires MRI with chemical shift imaging or biopsy for diagnosis, so this differential diagnosis should be maintained for homogeneous, low-enhancement solid masses.

References

• Silverman SG, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019;292(2):475-488
• Campbell SC, et al. AUA/SUO Guideline: Renal Mass and Localized Renal Cancer. J Urol. 2021;206(2):209-218
• Marconi L, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69(4):660-673
• Pierorazio PM, et al. Active surveillance for small renal masses. Rev Urol. 2015;17(1):13-19
• NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 4.2024

Read this lecture as Markdown